The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%. The young man died of acute ...

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne ...

Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.

The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the ...

Drugmakers are urging the Trump administration and EU officials to exclude medical goods from expanding tariffs wars ...

Most solar companies set the price according to the solar system's wattage. A solar installation's “cost per watt” is a little like the “price per square foot” when you buy a house.

The successful launch of Elevidys, Sarepta’s gene therapy for DMD, has been a key driver of the company’s recent performance. Following the full-label expansion for Elevidys in DMD patients aged 6 ...

As consumers cope with lingering cost of living pressures and the potential impact of tariffs, CBS News is tracking the change in prices of everyday household expenses — from food to utilities ...